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Daniel C Cattran, MD, FRCPC (Work Group Co-Chair), is
a graduate of the University of Toronto Medical School and
completed his postgraduate training both in Toronto, Canada
and Sydney, Australia. He is currently a Professor of Medicine
at the University of Toronto and a senior scientist at the
Toronto General Research Institute. His administrative roles
have included Chairman of the Royal College of Canada
specialty program in nephrology, the renal transplant
program of the Toronto General Hospital, and Director
of the postgraduate education program in nephrology at
the University of Toronto. Dr. Cattran is a member of
postgraduate education committee of the American Society
of Nephrology and he also currently serves on the KDIGO
Board.
Dr. Cattran’s major research work has been in field of
GN. He was the principal organizer and present Chair of
the Toronto Glomerulonephritis Registry, which currently
includes over 11,000 cases of biopsy-proven GN. His
current research activities also include chairing the steering
committee of NEPTUNE, an NIH-sponsored North
American Consortium of 15 Centers focused on investi-
gating the molecular mechanisms of the nephrotic syndrome
and in particular the histologic variants, MN and FSGS.
His own research is currently examining the role of ACTH
as new therapy for IMN, and Dr. Cattran is lead investi-
gator of a North American validation study of the new
Oxford classification of IgAN. Grant support for his work
has come from the Kidney Foundation of Canada, PSI,
the National Institutes of Health, and the Canadian Institutes
for Health Research. He has published over 190 articles in
peer-reviewed journals and has been the principal author of
more than 20 book chapters, as well as multiple reviews
related to the natural history, outcome, and treatment studies
in GN.
In recognition of his career in clinical investigation, the
Kidney Foundation of Canada recently awarded him their
prestigious Medal for Research Excellence. He has also been
active in volunteer work, in particular, the Kidney Founda-
tion of Canada and has held a number of positions including
the chair of their Medical Advisory Board. The Foundation’s
award, ‘‘Volunteer of the Year’’, acknowledged his contri-
butions to this organization. He has also held a number of
positions in the Canadian Society of Nephrology, including a
term as President.
Advisor/Consultant: Genentech; Osprey; Questcor; Roche; Vifor
Speaker: Novartis
Grant/Research Support: Amgen
John Feehally, DM, FRCP (Work Group Co-Chair), is
Professor of Renal Medicine at The John Walls Renal Unit,
Leicester General Hospital, UK. He received training in
nephrology in Manchester and Leicester, UK, and in Boston,
MA, USA, and was appointed Consultant Nephrologist at
Leicester General Hospital in 1988. In 1999 he became
Honorary Professor of Renal Medicine at the University of
Leicester, UK. His particular clinical interests include topics
such as GN and kidney transplantation. He has an active
laboratory research program with a focus on immune renal
disease, particularly IgAN, and maintains an epidemiological
and clinical research interest in ethnic variations in renal
disease.
Professor Feehally is Co-Editor of Comprehensive Clinical
Nephrology, 4th Edition. He is President of the International
Society of Nephrology (2011-2013), served as President of the
Renal Association in the UK (2004-2007), and has been a
member of the Renal Advisory Group at the UK Department
of Health since 2003.
Dr Feehally reported no relevant financial relationships
H Terence Cook, MBBS, MRCP, MRCPath, FRCPath,
FMedSci, is Professor of Renal Pathology at Imperial
College of Medicine and Deputy Director of the Centre
for Complement and Inflammation Research at Imperial
College, London, UK. Dr. Cook completed his under-
graduate studies at New College, University of Oxford
and received his medical degree from St. Mary’s Hospital
Medical School in London, UK. His major research
interests include the studying of pathological mechanisms
of injury in glomerulonephritis and the role of macrophages,
antibodies, Fc receptors, complement, and other mediators in
the disease process. He also maintains an active interest in the
use of histological features from human renal biopsies to
predict response to treatments. In particular, he is presently
conducting transcriptome analysis from renal biopsies for the
diagnosis of transplant rejection. Dr. Cook is currently the
President of Renal Pathology Society and a member of
committees including, ISN COMGAN Subcommittee on
Renal Pathology; Royal College of Pathologists Ethics
Committee; and Renal Association International Committee.
He has authored more than 200 publications and served as a
consensus working group member of the International IgA
Nephropathy Network, which recently developed the Oxford
Classification of IgA Nephropathy.
Advisor/Consultant: Roche
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Fernando C Fervenza, MD, PhD, is Professor of Medicine
and Section Head, Parenchymal Renal Division at Mayo
Clinic College of Medicine in Rochester, MN, USA. He
received his medical training at the Medical School of the
Pontificia Universidade, Brazil and completed his doctoral
degree from University of Oxford, UK and fellowship studies
from Stanford University. His primary research interest lies in
the area of parenchymal renal disease with a focus on the
glomerulopathies. Specifically, Dr. Fervenza is a current
principal investigator in a number of clinical trials examining
the efficacy of ocrelizumab in class III or IV nephritis; the use
of rituximab as induction therapy in patients with lupus
membranous patients; and the effectiveness of ACTH in
lowering proteinuria in patients with IMN. In addition
to authoring more than 100 peer-reviewed publications,
Dr. Fervenza has been actively involved in the mentoring of
residents, nephrology fellows, and visiting physicians. Since
2001, he has organized an annual nephrology up-to-date
course in Brazil with the aim of fostering scientific
improvement in the Brazilian nephrology community. In
recognition for his multitude of contributions, Dr. Fervenza
was awarded the Career Development Award in 2007 by the
Mayo Foundation and most recently received the Laureate
Award from the Mayo Clinic.
Advisor/Consultant: Genentech; Questcor
Grant/Research Support: Genentech; Novartis; Questcor;
Roche; Teva
Ju¨rgen Floege, MD, graduated from the Hannover Medical
School in Germany in 1984 and subsequently received his
clinical training at the Hannover Medical School. His
particular interest in renal diseases and renal replacement
therapies developed during various research periods in
physiology, pharmacology, nephrology, and pathology at the
Hannover Medical School, Germany; the Albert Einstein
College of Medicine, New York; and the University of
Washington, Seattle, WA, USA. He was appointed as head
of the Division of Nephrology and Immunology at the
University of Aachen, Germany in 1999. In 2001, he became
the Vice Dean of the Medical School, and since 2004, a
Director of a government-funded center grant on chronic
inflammation.
Professor Floege is an active member of several nephro-
logy societies, including the American Society of Nephrology,
ISN, and the European Renal Association (ERA-EDTA). He
is a current member of the ERA-EDTA scientific advisory
board, Co-Chair of the World Congress of Nephrology
(Vancouver 2011) and former ERA-EDTA and ISN council
member. In addition, he is a founding member and vice
president of the German Society of Nephrology, since 2008.
Together with Professors Richard Johnson and John Feehally
he is editor of the best-selling textbook Comprehensive
Clinical Nephrology. Finally, Professor Floege is one of two
deputy editors of the ERA-EDTA journal Nephrology Dialysis
Transplantation and a member of the editorial board of
several other journals, including Journal of the American
Society of Nephrology, Kidney International, Nature Clinical
Practice Nephrology, Journal of Nephrology, and Clinical
Nephrology.
His research interests encompass both basic research (i.e.,
studies on growth factors, cytokines, angiogenesis, stem cells
and fibrosis in the course of renal disease) as well as clinical
problems such as immune-mediated renal disease, bone and
mineral disorders and cardiovascular risk factors in dialysis
patients. Dr. Floege’s scientific work encompasses 300
original papers, reviews and editorials, and 40 book chapters.
Advisor/Consultant: Amgen; Boehringer Ingelheim; Frese-
nius; Genzyme; Pharmalink; Vifor
Speaker: Amgen; Fresenius; Genzyme; Vifor
Debbie S Gipson, MD, MS, is Associate Professor, Division
of Nephrology in the Department of Pediatrics at University
of Michigan, MI, USA, and Director for Research Design,
Epidemiology, Biostatistics and Clinical Research Ethics Core
at Michigan Institute for Clinical and Health Research. After
obtaining a medical degree from Indiana University School of
Medicine, Dr. Gipson completed her fellowship in pediatric
nephrology at University of Washington, Seattle, WA, USA,
where she also received her master’s degree in epidemiology.
She is currently a member of NIH FSGS Clinical Steering
Committee and the Chair of its Clinical Management
Committee. In addition, she is a research investigator in
several clinical trials which strive to better assess risk factors
for progression of chronic kidney disease in children and
identify therapeutic options for patients with multi-drug
resistant FSGS. Dr. Gipson is also Co-Director for Pediatric
Clinical Research, Nephrotic Syndrome Study Network
(NEPTUNE) whose goal is to bring clinical and translational
scientists together with the aim to educate patients with
FSGS, MN, and MCD.
Dr Gipson reported no relevant financial relationships
Richard J Glassock, MD, MACP, is currently Professor
Emeritus at the David Geffen School of Medicine at UCLA
and an internationally recognized expert in the field of
glomerular diseases and clinical nephrology. He has published
over 400 original papers, books, book chapters, reviews, and
served as Co-Editor in a recent text, Treatment of Primary
Glomerulonephritis (2nd Edition). Professor Glassock has
lectured in more than 90 countries and has been a visiting
professor at over 100 academic institutions. Throughout his
career, he has trained over 50 nephrologists.
Professor Glassock has received many awards, including
the David Hume Memorial Award of the National Kidney
Foundation, and the Robert Narins Award of the American
Society of Nephrology. He is the founding Editor-in-Chief
of the NephSAP and sits on the editorial board of Journal
of the American Society of Nephrology and Journal of
Nephrology.
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Advisor/Consultant: Aspreva (Vifor Pharma); BioMarin;
Bristol-Myers Squibb; ChemoCentryx; Eli Lilly; FibroGen;
Genentech; La Jolla Pharmaceutical; Lighthouse Learning;
National Institutes of Health; Novartis; Questcor; Wyeth
Board of Directors/Advisory Board: American Renal Associ-
ates; Los Angeles Biomedical Research Institute; University
Kidney Research Organization; Wyeth
Ownership Interests: La Jolla Pharmaceutical; Reata
Honoraria: American Society of Nephrology
Employment: American Journal of Nephrology; American
Society of Nephrology; Lighthouse Learning; UpToDate
Royalties: Oxford University Press
Elisabeth M Hodson, MBBS, FRACP, is a consultant
pediatric nephrologist at the Children’s Hospital at Westmead
in Sydney, Australia and was Head of the Department of
Nephrology from 1995 to 2008. Her research interests have
included CKD-metabolic bone disease, antenatal diagnosis of
urinary tract abnormalities, growth in children with chronic
kidney disease, and since 2002, a cohort study of antecedents
of kidney disease in Aboriginal and non-Aboriginal children
and young people. Since 2000, she has been an editor for the
Cochrane Collaboration’s Renal Review Group, which is
based in the Centre for Kidney Research at the Children’s
Hospital at Westmead. Dr. Hodson has written and/or
updated fourteen systematic reviews of RCTs of therapies
for kidney disease for the Cochrane Renal Group. These
include systematic reviews on the management in children of
SSNS with corticosteroids and corticosteroid-sparing agents,
of SRNS, and of HSP nephritis.
Dr Hodson reported no relevant financial relationships
Vivekanand Jha, MD, DM, FRCP, FAMS, is Additional
Professor of Nephrology and Coordinator of Stem Cell
Research Facility at the Postgraduate Institute of Medical
Education & Research, Chandigarh, India. Dr Jha has held
numerous committee positions in professional bodies such
as The Transplantation Society, International Society of
Nephrology and, most recently, a Steering Committee
member of the World Health Organization initiative on data
harmonization in transplantation. His ongoing research
projects include the development of optimal strategies of
immunosuppressive drug use after kidney transplantation by
pharmacogenomic approaches, and the studying of bone
mineral density and histomorphometry in chronic kidney
failure and its evolution after transplantation. He is Editor of
The Cochrane Renal Group and a frequent peer reviewer for
14 journals. Dr. Jha has authored over 160 publications and
25 book chapters, and serves as an editor of an upcoming
textbook, Management of Kidney Transplant Recipient. He
was awarded Fellowships from The Royal Society of
Physicians (London) and The National Academy of Medical
Sciences (India) in 2009 and 2010, respectively.
Dr Jha reported no relevant financial relationships
Philip Kam-Tao Li, MD, FRCP, FACP, is the Chief of
Nephrology & Consultant Physician of the Department of
Medicine and Therapeutics at the Prince of Wales Hospital,
Hong Kong. He is also the Honorary Professor of Medicine at
the Chinese University of Hong Kong.
Prof. Li dedicates his efforts to promoting nephrology
both locally and internationally. He is the Past Chairman
of the Hong Kong Society of Nephrology and presently
the Executive Committee Member of the ISN and current
President of the Hong Kong Transplantation Society. Prof.
Li serves on the Board of Directors for KDIGO and is a
Steering Committee Member for World Kidney Day 2010 as
well as the Executive Committee Member of the Asian Forum
for CKD Initiatives. He also sits on the Executive Council of
the Asian Pacific Society of Nephrology, the Council of
International Society for Peritoneal Dialysis, and serves as
the Honorary Secretary at the Hong Kong College of
Physicians.
Prof. Li had been President of the Organizing Committees
for the ISN 2004 Conference on Prevention of Progression of
Kidney Diseases and the 11th International Congress of
International Society for Peritoneal Dialysis in 2006. He was
also the Scientific Vice-President and Program Chair for the
2nd Congress of the International Society for Hemodialysis
in 2009. Prof. Li is now the Chairman of the Organizing
Committee for the World Congress of Nephrology 2013,
which will be held in Hong Kong.
Prof. Li is the founding Editor-in-Chief of the Hong Kong
Journal of Nephrology, Deputy Editor of Nephrology, and
Editor of Nephrology Dialysis Transplantation and the
International Journal of Artificial Organs. He is on the
Editorial Boards of Clinical Nephrology, Peritoneal Dialysis
International, Nephron Clinical Practice, Chinese Journal
of Nephrology, Dialysis & Transplantation, Medical Progress,
Indian Journal of Peritoneal Dialysis, and is a regular
reviewer for all the major nephrology journals. He has
published over 380 original and review articles in peer-
reviewed journals, two books and 17 book chapters, and has
given lectures to over 100 international congresses and
meetings.
His research interests include many aspects of peritoneal
dialysis, such as residual renal function, cardiovascular
disease, connectology, peritonitis, biocompatible solutions
adequacy; cardiovascular mortality in dialysis patients; IgAN;
prevention of progression of CKD; diabetes in kidney failure;
immunogenetics of nephropathies; and drug pharmaco-
kinetics and complications after transplantation.
Advisor/Consultant: Baxter Healthcare
Speaker: Baxter Healthcare; Fresenius; Roche
Grant/Research Support: Baxter Healthcare
Zhi-Hong Liu, MD, earned her medical degree from Xinjiang
University School of Medical in 1982, and postgraduate
degree at University of Secondary Military School of
Medicine, Shanghai, China, in 1989. She worked as a research
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associate at the NIH, NIDDK, USA (1993-1995) and a
visiting scholar in the Division of Nephrology, University of
Washington, Seattle, WA, USA (1996).
Dr. Liu was appointed Professor of Medicine at Nanjing
University in 1996 and became Adjunct Professor of
Medicine at Brown University in 2008. In 2003, she was also
elected as Academician in Chinese Academy of Engineering.
Her primary interest is in the field of renal disease, with
special interest in GN, including IgAN, LN, MN, FSGS, and
diabetic and metabolic renal disease. She has published 390
articles, authored two books, and contributed chapters to
nephrology textbooks. Dr. Liu also served on the editorial
boards of several peer-reviewed journals, including as editor-
in-chief of the Chinese Journal of Nephrology Dialysis &
Transplantation. She was honored with the National Science
and Technology Progress Award of China; the National
Young Investigator Award and National Outstanding In-
dividual Award in Science and Technology from the China
Association for Science and Technology; and the Guanghua
Engineering & Technological Science Award from Chinese
Academy of Engineering. She is the President-Elect of the
Chinese Society of Nephrology.
Dr. Liu directs one of the most productive renal patient
care and research programs in China, the Research Institute
of Nephrology, Jinling Hospital at the Nanjing University
School of Medicine and she is the Board member of
Academic Degrees Committee, Nanjing University. Dr. Liu
has served on several international committees related to
scientific programs and global scientific interactions and she
worked as Scientific Program Committee member of the
World Congress of Nephrology in 2007. She has been a
KDIGO Board Member since 2009 and presently chairs the
annual meeting of ‘‘Forefronts in Glomerular Disease—
Nanjing Forum’’, which has been endorsed as ISN GO
Continuing Medical Education Course since 2006.
Dr Liu reported no relevant financial relationships
Sergio A Mezzano, MD, FASN, FACP, is Cathedratic
Professor of Medicine and Chairman, Division of Nephrol-
ogy at Universidad Austral in Valdivia, Chile. He completed
his medical studies at Universidad Cato´lica de Chile and
nephrology fellowship at University of Cincinnati, Ohio,
USA. Dr. Mezzano has authored over 110 publications and
book chapters on topics spanning immunopathogenesis of
glomerular diseases, role of proteinuria and RAS activation
in progression of CKD and mechanisms of renal fibrosis,
epithelial mesenchymal transdifferentiation, and interstitial
inflammatory infiltration. He has served as Past President of
both the Chilean Society of Nephrology (1996-1998) and
Latin American Society of Nephrology (2002-2004). In 2002,
he was honored with an International Medal Award by the
NKF and received the Laureate Award from the American
College of Physicians in 2007.
Advisor/Consultant: Fresenius
Patrick H Nachman, MD, is Professor of Medicine at the
University of North Carolina at Chapel Hill, NC, USA. He
graduated from Boston University School of Medicine and
received fellowship training at University of North Carolina
at Chapel Hill. His research interests encompass many areas,
including the participation of a number of clinical trials for
treatment of FSGS, polycystic kidney disease, IMN, diabetic
nephropathy, LN, and ANCA vasculitis. As an author of
over 50 publications, he maintains a firm commitment to
postgraduate education both at the national and interna-
tional level. Dr. Nachman was awarded the Internal Medicine
Housestaff Faculty Award in 2007 and acknowledged in Best
Doctors in America from 2008–2010.
Grant/Research Support: Alexion
Manuel Praga MD, PhD, is Professor of Medicine at the
Complutense University, and Chief of the Nephrology
Division at the Hospital 12 de Octubre in Madrid, Spain.
He is member of the Scientific Committee at the ‘‘Instituto
de Investigacio´n Hospital 12 de Octubre’’. He obtained his
medical degree from the University of Valladolid and
completed a nephrology fellowship at Hospital Puerta de
Hierro, Madrid, Spain. Dr Praga is a founding member and
coordinator of the Group for the Study of Glomerular
Diseases of the Spanish Society of Nephrology (GLOSEN).
He has authored more than 200 peer-reviewed publications
and numerous book chapters, and has received many awards,
including the ‘‘In˜igo Alvarez de Toledo’’ award to Clinical
Investigation in 2000 and 2008. Dr. Praga has served on the
Directory Board of the Spanish Society of Nephrology, and
also sits as an editorial board member and reviewer for
international journals. His current research activities focus on
primary and secondary glomerular diseases, renal complica-
tions of obesity, diabetic nephropathy, role of proteinuria in
the progression of renal damage, interstitial renal diseases,
and renal transplantation.
Advisor/Consultant: Aspreva (Vifor Pharma); Novartis;
Roche
Speaker: Astellas; Novartis; Roche
Grant/Research Support: Astellas; Novartis; Roche; Wyeth
Jai Radhakrishnan, MD, MS, MRCP, FACC, FASN, is
Associate Professor of Clinical Medicine and the Director
of the Nephrology Fellowship Training Program at Columbia
University, NY, USA. He acquired his medical school and
internal medicine training in India, Great Britain, and the
USA, and later completed a nephrology fellowship at the
Massachusetts General Hospital in Boston and Columbia-
Presbyterian Medical Center in New York. His clinical and
research interests are therapy of glomerular diseases and
intensive-care nephrology. Dr. Radhakrishnan is an associate
editor of Kidney International and the editor-in-chief of the
Nephrology Gateway (the ISN website). His commitment to
medical education and patient care is exemplified by his
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numerous teaching awards and his inclusion in the Who’s
Who Among America’s Teachers & Educators and America’s
Best Doctors.
Advisor/Consultant: Genentech
Brad H Rovin, MD, FACP, FASN, is Professor of Medicine and
Pathology, Vice-Chairman of Research for Internal Medicine,
and Director, Division of Nephrology at The Ohio State
University College of Medicine, OH, USA. He received his
medical degree from University of Illinois and completed
nephrology fellowship training at Washington University School
of Medicine in St. Louis, Missouri, USA. As a leading authority
on treatment for lupus, Dr. Rovin has conducted
a randomized controlled study (LUNAR) examining the
effectiveness of rituximab in lupus nephritis patients already
receiving MMF and corticosteroids. In addition, he is also a
primary investigator in a multicenter RCTevaluating the efficacy
and safety of rituximab in patients with moderate to severe SLE.
With over 120 authored publications, Dr. Rovin has served on
the editorial boards of American Journal of Kidney Disease,
Clinical Nephrology, Journal of the American Society of Nephrol-
ogy, Kidney International and as a manuscript reviewer for 16
other journals. He is also a member of numerous professional
societies, including the Scientific Advisory Board of the Lupus
Foundation of America and various NIDDK Study Sections.
Dr. Rovin is a past recipient of the NKF Young Investigator
Award and Clinical Scientist Award, and has appeared in
multiple editions of America’s Best Doctors since 2005.
Advisor/Consultant: Biogen Idec; Centocor; Genentech;
Osprey; Questcor; Teijan Pharmaceuticals; Teva
Grant/Research Support: Biogen Idec; Centocor; Genentech;
Questcor; Roche; Teva
Data Monitoring Committee: Celtic; Eli Lilly
Ste´phan Troyanov, MD, is Assistant Professor of Clinical
Medicine at Universite´ de Montre´al, Quebec, Canada and
nephrologist at Hoˆpital du Sacre´-Coeur de Montre´al.
Dr. Troyanov completed his medical studies at Universite´
de Montre´al and received fellowship training at University of
Toronto, Canada. His earlier research centered on ascertain-
ing the determinants of remission in proteinuria in primary
glomerular disease. Currently, he is investigating the use of
urinary inflammatory markers in predicting the outcome of
progressive glomerular disease, and is conducting an
European validation study on the Oxford Classification of
IgAN. Dr. Troyanov received the Clinician Research Award
twice from Fonds de la Recherche en Sante´ du Que´bec, an
agency of the Government of Que´bec, and the Young
Nephrologist Prize from Socie´te´ Que´be´coise de Ne´phrologie.
Dr Troyanov reported no relevant financial relationships
Jack F M Wetzels, MD, PhD, was born in Heerlen, The
Netherlands. He studied Medicine at the University of
Nijmegen, and received his MD in 1980. He undertook his
training in Internal Medicine and Nephrology at the
Radboud University Nijmegen Medical Center and later
received his PhD in 1989. From 1990 to 1992, he studied
ischemic renal tubular injury as a postdoctoral fellow under
the supervision of Robert W Schrier at the University of
Colorado Health Sciences Center in Denver, CO, USA. Since
1992, he has been working as a nephrologist and was
appointed Professor of Nephrology in the Department of
Nephrology at Radboud University Nijmegen in 2002.
Professor Wetzels is committed to teaching and research,




Grant/Research Support: Alexion; Amgen; Genzyme; Roche
KDIGO Chairs
Kai-Uwe Eckardt, MD, is Professor of Medicine and Chief
of Nephrology and Hypertension at the University of
Erlangen–Nuremberg, Germany. He received his MD from
the Westfa¨lische Wilhelms-Universita¨t Mu¨nster, Germany. In
1993, following postgraduate training in internal medicine,
pathology and physiology, he was appointed Assistant
Professor of Physiology at the University of Regensburg,
Germany. Subsequently, he continued his training in internal
medicine and nephrology at the Charite´, Humboldt Uni-
versity in Berlin, where he was appointed Associate Professor
of Nephrology in 2000. His major scientific interests are in
the molecular mechanisms and physiological/pathophysiolo-
gical relevance of oxygen sensing and the management of
anemia. As such, he has contributed to the development of
the European Best Practice Guidelines for Anemia Manage-
ment and participated in the CREATE and TREAT trial
studies. Professor Eckardt is Subject Editor of Nephrology
Dialysis Transplantation, and serves on the editorial board of
several other journals. He has also authored book chapters
and most recently served as a Co-Editor of the text Studies on
Renal Disorders. Dr. Eckardt is a member of the executive
committee of KDIGO.
Advisor/Consultant: Affymax; Amgen; Hexal Sandoz;
Johnson & Johnson; Roche
Speaker: Amgen; Janssen Cilag; Johnson & Johnson; Roche
Grant/Research Support: Roche
Bertram L Kasiske, MD, is Professor of Medicine at the
University of Minnesota, USA. He received his medical
degree from the University of Iowa and completed his
Internal Medicine residency and fellowship training in
Nephrology at Hennepin County Medical Center where he
is currently Director of Nephrology.
Dr Kasiske is former Deputy Director of the United States
Renal Data System and former Editor-in-Chief of The
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American Journal of Kidney Diseases. He has served as
Secretary/Treasurer and on the Board of Directors of the
American Society of Transplantation, and on the Organ
Procurement and Transplantation Network/United Network
of Organ Sharing Board of Directors, and the Scientific
Advisory Board of the National Kidney Foundation. He
is currently serving on the Board of Councilors of the
International Society of Nephrology. He is the Principal
Investigator for a National Institutes of Health-sponsored,
multi-center study of long term outcomes after kidney
donation. He is the Director of the Scientific Registry of
Transplant Recipients. He has over 160 scientific publications
in major peer reviewed journals, and 230 review articles,
editorials and textbook chapters. Dr Kasiske is also a recipient
of the NKF’s Garabed Eknoyan Award in 2003.
Advisor/Consultant: Litholink
Grant/Research Support: Bristol-Myers Squibb; Merck-
Schering Plough
Evidence Review Team
Ethan M Balk, MD, MPH, is the Director, Evidence-
based Medicine at the Tufts Center for Kidney Disease
Guideline Development and Implementation, in Boston,
MA, USA, Associate Director of the Tufts Evidence-based
Practice Center, and Assistant Professor of Medicine at Tufts
University School of Medicine. Dr Balk graduated from Tufts
University School of Medicine and completed a fellowship in
Clinical Care Research. As Project Director, he plays a
substantial role in providing methodological expertise in the
guideline development process and assists in the collection,
evaluation, grading, and synthesis of evidence and the
revisions of the final evidence report. Dr Balk also provides
methodological guidance and training for Work Group
members during meetings regarding topic refinement, key
question formulation, data extraction, study assessment,
evidence grading, and recommendation formulation. His
primary research interests are evidence-based medicine,
systematic review, clinical practice guideline development,
and critical literature appraisal.
Dr Balk reported no relevant financial relationships
Gowri Raman, MD, MS, is Assistant Professor of Medicine at
Tufts University School of Medicine, Boston, MA, USA and
Assistant Director, Tufts Evidence-based Practice Center at
the Center for Clinical Evidence Synthesis. She completed her
Clinical and Translational Science Research fellowship in the
Institute for Clinical Research and Health Policy Studies at
Tufts Medical Center. Her primary research interests are
health technology assessment, systematic review and clinical
practice guideline development.
Dr Raman reported no relevant financial relationships
Dana C Miskulin, MD, MS, is Assistant Professor of Medicine
at Tufts University School of Medicine, Boston, MA, USA. She
completed a fellowship in Clinical Care Research and
participated in the conduct of systematic reviews and critical
literature appraisals for this guideline. Her primary research
interests are in comparative effectiveness research in dialysis
patients, blood pressure treatment in dialysis patients, and
autosomal dominant polycystic kidney disease.
Dr Miskulin reported no relevant financial relationships
Aneet Deo, MD, MS, served as a research fellow at the Tufts
Center for Kidney Disease Guideline Development and
Implementation in Boston, MA. She participated in the
conduct of systematic reviews and critical literature appraisals
for this guideline. Dr Deo was awarded a Master of Science in
Clinical Research for her thesis on ‘‘Loss to Analysis in
Randomized Controlled Trials of Chronic Kidney Disease’’.
Dr Deo reported no relevant financial relationships
Amy Earley, BS, is a project coordinator at the Tufts Center
for Kidney Disease Guideline Development and Implementa-
tion in Boston, MA, USA. She assists in the development of
clinical practice guidelines and conducts systematic reviews
and critical literature appraisals.
Ms Earley reported no relevant financial relationships
Shana Haynes, MS, DHSc, is a research assistant at the Tufts
Center for Kidney Disease Guideline Development and
Implementation in Boston, MA, USA. She assists in the
development of clinical practice guidelines and conducts
systematic reviews and critical literature appraisals.
Dr Haynes reported no relevant financial relationships
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